Investigating the effects of nintedanib on biomarkers of extracellular matrix turnover in patients with IPF: Design of the randomised placebo-controlled INMARK®trial

BMJ Open Respiratory Research

Volumn 5, Issue 1, 2018, Pages

  Maher, Toby M ^a,b   Stowasser, Susanne ^c   Nishioka, Yasuhiko ^d   White, Eric S ^e   Cottin, Vincent ^f   Noth, Imre ^g   Selman, Moisés ^h   Blahova, Zuzana ⁱ   Wachtlin, Daniel ^c   Diefenbach, Claudia ^c   Jenkins, R Gisli ^j  

^a ROYAL BROMPTON AND HAREFIELD NHS FOUNDATION TRUST   (United Kingdom)

^b NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^c BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

^d UNIVERSITY OF TOKUSHIMA   (Japan)

^e UNIVERSITY OF MICHIGAN   (United States)

^f UNIVERSITÉ LYON 1   (France)

^g UNIVERSITY OF VIRGINIA   (United States)

^h INSTITUTO NACIONAL DE ENFERMEDADES RESPIRATORIAS   (Mexico)

ⁱ BOEHRINGER INGELHEIM RCV GMBH AND CO KG   (Austria)

^j UNIVERSITY OF NOTTINGHAM   (United Kingdom)

more..

Author keywords

Interstitial fibrosis

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BIOLOGICAL MARKER; NINTEDANIB; PLACEBO; VASCULOTROPIN;

ADULT; ARTICLE; CONTROLLED STUDY; DISEASE EXACERBATION; DOUBLE BLIND PROCEDURE; EXTRACELLULAR MATRIX; FIBROSING ALVEOLITIS; FOLLOW UP; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HUMAN; INFORMED CONSENT; MORTALITY; PATHOGENESIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCREENING; TURNOVER RATE;

EID: 85052670322     PISSN: None     EISSN: 20524439     Source Type: Journal    
DOI: 10.1136/bmjresp-2018-000325     Document Type: Article

References (39)

1. Raghu G, Collard HR, Egan JJ, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 2011;183:788-824.
2. Schmidt SL, Tayob N, Han MK, et al. Predicting pulmonary fibrosis disease course from past trends in pulmonary function. Chest 2014;145:579-85.
3. Ley B, Bradford WZ, Vittinghoff E, et al. Predictors of mortality poorly predict common measures of disease progression in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2016;194:711-8.
4. Peljto AL, Zhang Y, Fingerlin TE, et al. Association between the MUC5B promoter polymorphism and survival in patients with idiopathic pulmonary fibrosis. JAMA 2013;309:2232-9.
5. Herazo-Maya JD, Sun J, Molyneaux PL, et al. Validation of a 52-gene risk profile for outcome prediction in patients with idiopathic pulmonary fibrosis: an international, multicentre, cohort study. Lancet Respir Med 2017;5:857-68.
6. Greene KE, King TE, Kuroki Y, et al. Serum surfactant proteins-A and-D as biomarkers in idiopathic pulmonary fibrosis. Eur Respir J 2002;19:439-46.
7. Yokoyama A, Kondo K, Nakajima M, et al. Prognostic value of circulating KL-6 in idiopathic pulmonary fibrosis. Respirology 2006;11:164-8.
8. Rosas IO, Richards TJ, Konishi K, et al. MMP1 and MMP7 as potential peripheral blood biomarkers in idiopathic pulmonary fibrosis. PLoS Med 2008;5:e93.
9. Richards TJ, Kaminski N, Baribaud F, et al. Peripheral blood proteins predict mortality in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2012;185:67-76.
10. Maher TM, Oballa E, Simpson JK, et al. An epithelial biomarker signature for idiopathic pulmonary fibrosis: an analysis from the multicentre PROFILE cohort study. Lancet Respir Med 2017;5:946-55.
11. Bjermer L, Lundgren R, Hallgren R. Hyaluronan and type III procollagen peptide concentrations in bronchoalveolar lavage fluid in idiopathic pulmonary fibrosis. Thorax 1989;44:126-31.
12. Molyneaux PL, Cox MJ, Willis-Owen SA, et al. The role of bacteria in the pathogenesis and progression of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2014;190:906-13.
13. Han MK, Zhou Y, Murray S, et al. Association between lung microbiome and disease progression in IPF: a prospective cohort study. Lancet Respir Med 2014;2:548-56.
14. Park HJ, Lee SM, Song JW, et al. Texture-based automated quantitative assessment of regional patterns on initial CT in patients with idiopathic pulmonary fibrosis: relationship to decline in forced vital capacity. AJR Am J Roentgenol 2016;207:976-83.
15. Salisbury ML, Lynch DA, van Beek EJ, et al. Idiopathic pulmonary fibrosis: the association between the adaptive multiple features method and fibrosis outcomes. Am J Respir Crit Care Med 2017;195:921-9.
16. Jacob J, Bartholmai BJ, Rajagopalan S, et al. Predicting outcomes in idiopathic pulmonary fibrosis using automated CT analysis. Am J Respir Crit Care Med 2018. Epub ahead of print.
17. White ES, Borok Z, Brown KK, et al. An American Thoracic Society official research statement: future directions in lung fibrosis research. Am J Respir Crit Care Med 2016;193:792-800.
18. King TE, Pardo A, Selman M. Idiopathic pulmonary fibrosis. Lancet 2011;378:1949-61.
19. Fernandez IE, Eickelberg O. New cellular and molecular mechanisms of lung injury and fibrosis in idiopathic pulmonary fibrosis. Lancet 2012;380:680-8.
20. Philp CJ, Siebeke I, Clements D, et al. Extracellular matrix cross-linking enhances fibroblast growth and protects against matrix proteolysis in lung fibrosis. Am J Respir Cell Mol Biol 2018;58:594-603.
21. Pardo A, Cabrera S, Maldonado M, et al. Role of matrix metalloproteinases in the pathogenesis of idiopathic pulmonary fibrosis. Respir Res 2016;17:23.
22. Karsdal MA, Krarup H, Sand JM, et al. Review article: the efficacy of biomarkers in chronic fibroproliferative diseases-early diagnosis and prognosis, with liver fibrosis as an exemplar. Aliment Pharmacol Ther 2014;40:233-49.
23. Kristensen JH, Karsdal MA, Genovese F, et al. The role of extracellular matrix quality in pulmonary fibrosis. Respiration 2014;88:487-99.
24. Jenkins RG, Simpson JK, Saini G, et al. Longitudinal change in collagen degradation biomarkers in idiopathic pulmonary fibrosis: an analysis from the prospective, multicentre PROFILE study. Lancet Respir Med 2015;3:462-72.
25. Hilberg F, Roth GJ, Krssak M, et al. BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy. Cancer Res 2008;68:4774-82.
26. Wollin L, Maillet I, Quesniaux V, et al. Antifibrotic and antiinflammatory activity of the tyrosine kinase inhibitor nintedanib in experimental models of lung fibrosis. J Pharmacol Exp Ther 2014;349:209-20.
27. Wollin L, Wex E, Pautsch A, et al. Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis. Eur Respir J 2015;45:1434-45.
28. Ackermann M, Kim YO, Wagner WL, et al. Effects of nintedanib on the microvascular architecture in a lung fibrosis model. Angiogenesis 2017;20:359-72.
29. Richeldi L, Costabel U, Selman M, et al. Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis. N Engl J Med 2011;365:1079-87.
30. Richeldi L, du Bois RM, Raghu G, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med 2014;370:2071-82.
31. Miller MR, Hankinson J, Brusasco V, et al. Standardisation of spirometry. Eur Respir J 2005;26:319-38.
32. Jones PW, Quirk FH, Baveystock CM. The St George's respiratory questionnaire. Respir Med 1991;85 Suppl B(Suppl B):25-31. discussion 33-37.
33. Eakin EG, Resnikoff PM, Prewitt LM, et al. Validation of a new dyspnea measure: the UCSD Shortness of Breath Questionnaire. University of California, San Diego. Chest 1998;113:619-24.
34. Stopfer P, Rathgen K, Bischoff D, et al. Pharmacokinetics and metabolism of BIBF 1120 after oral dosing to healthy male volunteers. Xenobiotica 2011;41:297-311.
35. Maher TM, Flaherty KR, Noble PW, et al. Effect of baseline FVC on lung function decline with nintedanib in patients with IPF. Eur Respir J 2015;46(Suppl. 59):OA4499.
36. Kolb M, Richeldi L, Behr J, et al. Nintedanib in patients with idiopathic pulmonary fibrosis and preserved lung volume. Thorax 2017;72:340-6.
37. Paterniti MO, Bi Y, Rekić D, et al. Acute exacerbation and decline in forced vital capacity are associated with increased mortality in idiopathic pulmonary fibrosis. Ann Am Thorac Soc 2017;14:1395-402.
38. Russell AM, Adamali H, Molyneaux PL, et al. Daily home spirometry: an effective tool for detecting progression in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2016;194:989-97.
39. Johannson KA, Vittinghoff E, Morisset J, et al. Home monitoring improves endpoint efficiency in idiopathic pulmonary fibrosis. Eur Respir J 2017;50:1602406.